
Analyn Lizaso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4395062/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	β-adrenergic receptor-stimulated lipolysis requires the RAB7-mediated autolysosomal lipid degradation. Autophagy, 2013, 9, 1228-1243.	4.3	102
2	Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. Journal of Thoracic Oncology, 2020, 15, 1369-1375.	0.5	68
3	Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted nextâ€generation sequencing. Histopathology, 2019, 75, 890-899.	1.6	55
4	Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 1027-1036.	0.5	55
5	Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Aging, 2020, 12, 3140-3155.	1.4	44
6	Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling. Thoracic Cancer, 2019, 10, 823-831.	0.8	39
7	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Modern Pathology, 2020, 33, 626-638.	2.9	38
8	Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. Cancer Biology and Medicine, 2019, 16, 556-564.	1.4	36
9	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunology, Immunotherapy, 2021, 70, 2517-2528.	2.0	34
10	The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. Journal of Translational Medicine, 2019, 17, 298.	1.8	33
11	Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted DeepÂSequencing. Journal of Molecular Diagnostics, 2020, 22, 860-870.	1.2	33
12	The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer, 2020, 146, 165-173.	0.9	32
13	Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. Journal of International Medical Research, 2020, 48, 030006051988727.	0.4	27
14	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 935-944.	1.2	24
15	Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese nonâ€small cell lung cancer patients. Thoracic Cancer, 2020, 11, 103-112.	0.8	23
16	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. Frontiers in Oncology, 2020, 10, 1023.	1.3	22
17	Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance. Clinical Lung Cancer, 2021, 22, e390-e394.	1.1	19
18	Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. European Journal of Cancer, 2020, 141, 199-208.	1.3	18

ANALYN LIZASO

#	Article	IF	CITATIONS
19	Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. Lung Cancer, 2020, 148, 113-121.	0.9	17
20	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Translational Lung Cancer Research, 2019, 8, 1016-1028.	1.3	16
21	Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Medicine, 2021, 19, 206.	2.3	16
22	Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics. Journal of Cancer, 2021, 12, 4408-4417.	1.2	16
23	Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093577.	1.0	14
24	A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. Lung Cancer, 2020, 143, 55-59.	0.9	14
25	Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring nonâ€EML4â€ALK rearrangements detected from cerebrospinal fluid: A case report. Thoracic Cancer, 2020, 11, 176-180.	0.8	13
26	The <i>in cis</i> compound <i>EGFR</i> mutations in Chinese advanced non-small cell lung cancer patients. Cancer Biology and Therapy, 2019, 20, 1097-1104.	1.5	13
27	Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer. Frontiers in Oncology, 2021, 11, 618767.	1.3	12
28	A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients. Annals of Translational Medicine, 2020, 8, 1290-1290.	0.7	11
29	Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report. Annals of Translational Medicine, 2020, 8, 1099-1099.	0.7	11
30	Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma. Modern Pathology, 2022, 35, 1181-1192.	2.9	11
31	Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. Translational Lung Cancer Research, 2020, 9, 71-81.	1.3	9
32	Detecting Ultralow Frequency Mutation in Circulating Cellâ€Free DNA of Earlyâ€Stage Nonsmall Cell Lung Cancer Patients with Unique Molecular Identifiers. Small Methods, 2019, 3, 1900206.	4.6	7
33	Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma. Translational Lung Cancer Research, 2020, 9, 2356-2366.	1.3	7
34	Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative nonâ€small cell lung cancer patients. Cancer Medicine, 2021, 10, 8377-8386.	1.3	7
35	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. Npj Precision Oncology, 2022, 6, 20.	2.3	7
36	<p>Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer</p> . OncoTargets and Therapy, 2020, Volume 13, 7101-7109.	1.0	6

ANALYN LIZASO

#	Article	IF	CITATIONS
37	SIM2 maintains innate host defense of the small intestine. American Journal of Physiology - Renal Physiology, 2014, 307, G1044-G1056.	1.6	5
38	The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Translational Lung Cancer Research, 2021, 10, 326-339.	1.3	5
39	Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC. Journal of Thoracic Oncology, 2021, 16, 349-351.	0.5	5
40	Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report. OncoTargets and Therapy, 2019, Volume 12, 5305-5309.	1.0	4
41	Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. Lung Cancer, 2020, 150, 97-106.	0.9	4
42	Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report. Translational Lung Cancer Research, 2020, 9, 144-147.	1.3	4
43	Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer in Clinical Practice, 2021, 19, 7.	0.6	4
44	Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China. Annals of Translational Medicine, 2021, 9, 412-412.	0.7	3
45	Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report. Diagnostic Pathology, 2019, 14, 101.	0.9	2
46	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Lung Cancer, 2020, 146, 209-216.	0.9	2
47	The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report. Annals of Translational Medicine, 2021, 9, 80-80.	0.7	2
48	The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report. Cancer Biology and Therapy, 2021, 22, 1-4.	1.5	2
49	A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis― Lung Cancer, 2020, 150, 259-260.	0.9	0
50	A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis― Lung Cancer, 2020, 150, 254-255.	0.9	0
51	Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer. Annals of Palliative Medicine, 2020, 9, 1688-1695.	0.5	0
52	Third left pulmonary lobe. Thorax, 2021, 76, 525-525.	2.7	0
53	A Burning External Colon Cancer Patient With Diffuse Miliary Peritoneal Metastases. American Journal of Gastroenterology, 2021, 116, 632-632.	0.2	0